Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

NCT00575471 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Rivoglitazone HCl
DRUG: rivoglitazone HCl
DRUG: rivoglitazone HCl
DRUG: Placebo

Sponsor

Daiichi Sankyo Co., Ltd.